

# United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.		FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.	
10/528,460		12/19/2005	Stefan Golz	Le A 36 282	7581	
35969	7590	08/28/2006		EXAMINER		
JEFFREY	M. GRE	ENMAN	SHEN, BIN			
BAYER PHARMACEUTICALS CORPORATION				ART UNIT	PAPER NUMBER	
	400 MORGAN LANE WEST HAVEN, CT 06516			1655	TATER NOWIGER	
WESTIM	ver, or	00310		DATE MAILED: 08/28/2006	•	

Please find below and/or attached an Office communication concerning this application or proceeding.

	Application No.	Applicant(s)				
	10/528,460	GOLZ ET AL.				
Office Action Summary	Examiner	Art Unit				
	Bin Shen	1655				
The MAILING DATE of this communication app Period for Reply  A SHORTENED STATUTORY PERIOD FOR REPLY WHICHEVER IS LONGER, FROM THE MAILING DA - Extensions of time may be available under the provisions of 37 CFR 1.13 after SIX (6) MONTHS from the mailing date of this communication If NO period for reply is specified above, the maximum statutory period w - Failure to reply within the set or extended period for reply will, by statute, Any reply received by the Office later than three months after the mailing earned patent term adjustment. See 37 CFR 1.704(b).  Status	IS SET TO EXPIRE 1 MONTH( ATE OF THIS COMMUNICATION 36(a). In no event, however, may a reply be tim will apply and will expire SIX (6) MONTHS from cause the application to become ABANDONEI	S) OR THIRTY (30) DAYS, I. ely filed the mailing date of this communication. D (35 U.S.C. § 133).				
1) Responsive to communication(s) filed on	Responsive to communication(s) filed on					
2a) This action is <b>FINAL</b> . 2b) This	2b)☐ This action is non-final.					
3) Since this application is in condition for allowar	nce except for formal matters, pro	secution as to the merits is				
closed in accordance with the practice under E	x parte Quayle, 1935 C.D. 11, 45	3 O.G. 213. ·				
Disposition of Claims						
<ul> <li>4)  Claim(s) 1-26 is/are pending in the application.</li> <li>4a) Of the above claim(s) is/are withdraw</li> <li>5)  Claim(s) is/are allowed.</li> <li>6)  Claim(s) is/are rejected.</li> <li>7)  Claim(s) is/are objected to.</li> <li>8)  Claim(s) 1-26 are subject to restriction and/or example.</li> </ul>	vn from consideration.					
Application Papers						
9) The specification is objected to by the Examine 10) The drawing(s) filed on is/are: a) access applicant may not request that any objection to the Replacement drawing sheet(s) including the correct 11) The oath or declaration is objected to by the Examine	epted or b) objected to by the Eddrawing(s) be held in abeyance. See ion is required if the drawing(s) is obj	e 37 CFR 1.85(a). ected to. See 37 CFR 1.121(d).				
Priority under 35 U.S.C. § 119	• .					
<ul> <li>12) Acknowledgment is made of a claim for foreign</li> <li>a) All b) Some * c) None of:</li> <li>1. Certified copies of the priority documents</li> <li>2. Certified copies of the priority documents</li> <li>3. Copies of the certified copies of the prior application from the International Bureau</li> <li>* See the attached detailed Office action for a list</li> </ul>	s have been received. s have been received in Application ity documents have been receive u (PCT Rule 17.2(a)).	on No ed in this National Stage				
Attachment(s)						
1) Notice of References Cited (PTO-892) 2) Notice of Draftsperson's Patent Drawing Review (PTO-948) 3) Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08) Paper No(s)/Mail Date	4) Interview Summary Paper No(s)/Mail Da 5) Notice of Informal P 6) Other:					

Art Unit: 1655

#### DETAILED ACTION

## Election/Restrictions

Restriction is required under 35 U.S.C. 121 and 372.

This application contains the following inventions or groups of inventions which are not so linked as to form a single general inventive concept under PCT Rule 13.1.

In accordance with 37 CFR 1 .499, applicant is required, in reply to this action, to elect a single invention to which the claims must be restricted.

Group I, claim(s) 1, 4-11, drawn to a method of screening by detect binding to PDE11A polypeptide.

Group II, claim(s) 2, drawn to a method of screening by detecting the activity of PDE11A.

Group III, claim(s) 3, drawn to a method of screening by detecting the activity of PDE11A.

Group IV, claim(s) 12-17, drawn to a method of screening by detect binding to PDE11A polynucleotide.

Group V, claim 18, drawn to a method of diagnosing a disease by determining the amount of PDE11A polynucleotide.

Group VI, claim 19, drawn to a composition comprising a therapeutic agent which binds to a PDE11A polypeptide.

Group VII, claim 20-21, drawn to a composition comprising a therapeutic agent which regulates the activity of a PDE11A polypeptide.

Group VIII, claim 22, drawn to a composition comprising a polynucleotide.

Group IX, claim 23, drawn to a composition comprising a polypeptide.

Art Unit: 1655

Group X, claim 24, drawn to a method for the treatment of a disease.

Group XI, claim 25, drawn to a method for the preparation of a composition.

Group XII, claim 26, drawn to a method for the regulation of PDE11A activity in a mammal having a disease.

The inventions listed as Groups I-XIII do not relate to a single general inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, they lack the same or corresponding special technical features for the following reasons: there is no special technical feature since the composition of claim 23 and the method of claim 18 fail to share a common property or activity and fail to share a common structure. Thus, there is no special technical feature and lack of unity exists.

## Election of Species

This application contains claims directed to more than one species of the generic invention. These species are deemed to lack unity of invention because they are not so linked as to form a single general inventive concept under PCT Rule 13.1.

The species are as follows:

- -the type of disorders from among those instantly claimedi.e., peripheral and central nervous system, cardiovascular diseases, cancer, etc.-see, e.g., all the claims.
- -the one or more therapeutic agents instantly claimed (see, e.g., claim 21).

Applicant is required, in reply to this action, to elect a single species (i.e., elect a single disorder, from among those instantly claimed such as recited in claim 1, and elect one

Application/Control Number: 10/528,460

Art Unit: 1655

therapeutic agent from six agents instantly claimed in claim 21) to which the claims shall be restricted if no generic claim is finally held to be allowable. The reply must also identify the claims readable on the elected species, including any claims subsequently added. An argument that a claim is allowable or that all claims are generic is considered non-responsive unless accompanied by an election.

Upon the allowance of a generic claim, applicant will be entitled to consideration of claims to additional species which are written in dependent form or otherwise include all the limitations of an allowed generic claim as provided by 37 CFR 1.141. If claims are added after the election, applicant must indicate which are readable upon the elected species. MPEF § 809.02(a).

The following claim(s) are generic: 1, 2, 3, 12, 18, 19, 20, 21, 22, 23, 24, 25 and 26.

The species listed above do not relate to a single general inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, the species lack the same or corresponding special technical features for the following reasons: the numerous disorders instantly claimed (e.g., cardiovascular diseases vs. cancer vs urological diseases, etc) are different and distinct, each from the other (and, thus, do not share a special technical feature, each with the other).

Applicant is advised that the reply to this requirement to be complete must include an election of the invention to be Application/Control Number: 10/528,460

Art Unit: 1655

examined even though the requirement be traversed (37 CFR 1 .143).

Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a request under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(i).

#### Conclusion

Certain papers related to this application may be submitted to Art Unit 1636 by facsimile transmission. The faxing of such papers must conform with the notices published in the Official Gazette, 1156 OG 61 (November 16, 1993) and 1157 OG 94 (December 28, 1993) (see 37 C.F.R. § 1.6(d)). The official fax telephone number for the Group is 571-273-8300. NOTE: If Applicant does submit a paper by fax, the original signed copy should be retained by applicant or applicant's representative. NO DUPLICATE COPIES SHOULD BE SUBMITTED so as to avoid the processing of duplicate papers in the Office.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to (571) 272-0547.

Patent applicants with problems or questions regarding electronic images that can be viewed in the Patent Application Information Retrieval system (PAIR) can now contact the USPTO's Patent Electronic Business Center (Patent EBC) for assistance. Representatives are available to answer your questions daily from 6 am to midnight (EST). The toll free number is (866) 217-

Art Unit: 1655

9197. When calling please have your application serial or patent number, the type of document you are having an image problem with, the number of pages and the specific nature of the problem. The Patent Electronic Business Center will notify applicants of the resolution of the problem within 5-7 business days. Applicants can also check PAIR to confirm that the problem has been corrected. The USPTO's Patent Electronic Business Center is a complete service center supporting all patent business on the Internet. The USPTO's PAIR system provides Internet-based access to patent application status and history information. It also enables applicants to view the scanned images of their own application file folder(s) as well as general patent information available to the public.

For all other customer support, please call the USPTO Call Center (UCC) at 800-786-9199.

Any inquiry concerning rejections or objections in this communication or earlier communications from the examiner should be directed to Bin Shen, Ph.D., whose telephone number is (571) 272-9040. The examiner can normally be reached on Monday through Friday, from about 9:00 AM to about 5:30 PM. A phone message left at this number will be responded to as soon as possible (i.e., shortly after the examiner returns to her office).

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Dr. Terry McKelvey can be reached at (571) 272-0775.

MICHAEL MELLER PRIMARY EXAMINER

B Shen

AU 1655